Human Longevity's Largest Study of Its Kind Shows Early Detection of Disease and Disease Risks in Adults

• Study participants were evaluated with Human Longevity's multi-modal precision health platform, the Health Nucleus™
• The assessment yielded highly actionable findings, most of which were not previously known, resulting in early identification of disease and disease risk in conditions that can lead to pre-mature mortality in adults
• Study published in the Journal Proceedings of the National Academy of Sciences

Neurelis Announces FDA Approval for Seizure Rescue Treatment VALTOCO® (Diazepam Nasal Spray) that Incorporates the Science of Intravail® for Consistent and Reliable Absorption

-- VALTOCO (diazepam nasal spray) is approved by the U.S. Food and Drug Administration (FDA) for use by a care partner outside of the medical setting for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern

-- VALTOCO is the first nasal spray approved by the FDA as a rescue treatment for people with epilepsy aged 6 and older

-- VALTOCO's proprietary formulation including Intravail® has been shown to be generally safe and well tolerated

-- VALTOCO granted Orphan Drug Exclusivity by the FDA

NeoGenomics Acquires Oncology Division from Human Longevity for $37 Million

Significantly Enhances Next Generation Sequencing Capabilities for Pharmaceutical Customers

晨泰医药在研药品Zorifertinib专家顾问会议在沪召开

2020年1月3日，晨泰医药科技有限公司主导在研产品（AZD3759）的化学名Zorifertinib及该研究命名仪式日前在上海隆重举行。

Qpex was selected to be among Top Life Science Companies to Watch in 2020

BioSpace is present its NextGen Bio “Class of 2020,” a list of up-and-coming life sciences companies in North America that launched* no earlier than mid-2018.

Qpex Biopharma Announces Exercise of $20 Million Option by BARDA under its Other Transaction Authority (OTA) Agreement to Advance Multiple Products into Clinical Studies

Qpex Biopharma, Inc., a biopharmaceutical company dedicated to the discovery and development of innovative anti-infective therapies, today announced that the Biomedical Advanced Research and Development Authority (BARDA) has exercised its first agreement option, which will support advancing multiple programs into clinical studies.